World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 19 October 2017
Main ID:  NCT00746512
Date of registration: 03/09/2008
Prospective Registration: Yes
Primary sponsor: Merck Sharp & Dohme Corp.
Public title: A Study of the Effects of Oral Prednisone in Patients With Rheumatoid Arthritis (MK0000-088)
Scientific title: A Randomized, Double-Blind, Parallel Group, Placebo Controlled Study to Access the Effects of Oral Prednisone on Clinical Efficacy and the Power Doppler Ultrasound Signal of Synovium in Patients With Rheumatoid Arthritis
Date of first enrolment: September 2008
Target sample size: 45
Recruitment status: Completed
URL:  https://clinicaltrials.gov/show/NCT00746512
Study type:  Interventional
Study design:   
Phase:  Phase 1
Countries of recruitment
United Kingdom
Contacts
Name:     Medical Monitor
Address: 
Telephone:
Email:
Affiliation:  Merck Sharp & Dohme Corp.
Key inclusion & exclusion criteria

Inclusion Criteria:

- Patient is willing to limit alcohol intake to 3 or less beverages per day

- Patient agrees to use only acetaminophen/paracetamol for breakthrough pain

Exclusion Criteria:

- Patient has other inflammatory arthritis (e.g. lupus). Patient has had major surgery
or donated or lost 1 unit of blood in the last 4 weeks

- Patient has a history of drug or alcohol abuse in the last 2 years

- Patient has had a vaccine (with a live or attenuated virus) in the last two weeks



Age minimum: 18 Years
Age maximum: N/A
Gender: All
Health Condition(s) or Problem(s) studied
Rheumatoid Arthritis
Intervention(s)
Drug: Placebo Over-Encapsulated Tablets
Drug: Placebo Tablets
Drug: Prednisone 15 mg
Drug: Prednisone 7.5 mg
Primary Outcome(s)
Synovial Blood Flow [Time Frame: Baseline and Day 14]
Secondary Outcome(s)
Disease Activity Score 28 (DAS28) (C-reactive Protein [CRP]) [Time Frame: Baseline and Day 14]
Secondary ID(s)
0000-088
2008_531
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Ethics review
Results
Results available: Yes
Date Posted: 08/04/2011
Date Completed:
URL: https://clinicaltrials.gov/ct2/show/results/NCT00746512
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history